---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-25-000047"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:40:39.869046+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q1 revenue $62.5M (+24% YoY); net income $23.3M vs loss of $10.7M; LUPKYNIS sales up 25%

## Summary
- Total revenue $62.5M, up 24% YoY; net product sales of LUPKYNIS were $60.0M (+25% YoY).
- Net income $23.3M vs net loss $(10.7)M in Q1 2024; cash flow from operations $1.3M ($12.4M ex-restructuring).
- Cash and investments $312.9M; repurchased 5.8M shares for $47.4M in Q1.
- Full-year 2025 revenue guidance reaffirmed: $250-$260M; net product sales guidance $240-$250M.
- Initial Phase 1 results for dual BAFF/APRIL inhibitor AUR200 expected later this quarter.

## SEC filing metadata
- accession: 0001600620-25-000047
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000047/0001600620-25-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000047/auph-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-25-000047
- JSON: https://secwatch.observer/filing/0001600620-25-000047.json
- Plain text: https://secwatch.observer/filing/0001600620-25-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.